Journal Article Review Research Support, Non-U.S. Gov't Epublish 19 citations
PubMed: 36359837 DOI: 10.3390/cells11213444
The Role of HSP90 Inhibitors in the Treatment of Cardiovascular Diseases.
Cells 11(21)
Authors: Shiyu Qi, Guang Yi, Kun Yu, Chong Feng, Shoulong Deng
Affiliations
- College of Animal Science and Technology, China Agricultural University, Beijing 100193, China.
- Aurora Bioscience Co. Ltd. Suzhou 215000, China.
- National Health Commission (NHC) of China Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, China.
Abstract
Cardiovascular disease is the result of complicated pathophysiological processes in the tissues that make up the blood vessels and heart. Heat shock protein 90 (HSP90) can interact with 10% of the proteome and is the most widely studied molecular chaperone in recent years. HSP90 is extensively involved in the regulation of protein folding and intracellular protein stability, making HSP90 a hopeful target for the treatment of multiple cardiovascular diseases. Numerous client proteins of HSP90 have been identified in known cardiac disease pathways, including MAPK signaling, PI3K/AKT (PKB)/mTOR, and TNF-α signaling. Therefore, these pathways can be controlled by regulating HSP90. Among them, the activity of HSP90 can be regulated via numerous inhibitors. In this review, first, we will discuss the function of HSP90 and its role in pathological pathways. In addition, HSP90 plays a significant role in most cardiovascular diseases, including hypertension, pulmonary venous hypertension, atherosclerosis, and heart failure; next we will focus on this part. Finally, we will summarize the currently known HSP90 inhibitors and their potential in the treatment of heart disease.
MeSH
Heart Failure, Hypertension, Heart Diseases, Cardiovascular Diseases, Cells, Therapeutics, Heat-Shock Proteins
Cited by
- Downregulation of PGAM2 alleviates angiotensin II-induced cardiac hypertrophy by destabilizing HSP90 and inactivating the mTOR/IKKα signaling pathway. Int J Biol Sci, 2025
- Elevated plasma HSP90α as a prognostic marker in EGFR-mutant non-small cell lung cancer. Oncol Lett, 2025
- Advances in the structures, mechanisms and targeting of molecular chaperones. Signal Transduct Target Ther, 2025
- Small Molecule Screening Identifies HSP90 as a Modifier of RNA Foci in Myotonic Dystrophy Type 1. Mol Cell Biol, 2025
- Fibroblast-derived extracellular vesicles as trackable efficient transporters of an experimental nanodrug with fibrotic heart and lung targeting. Theranostics, 2024
- Plasma proteins associated with plant-based diets: Results from the Atherosclerosis Risk in Communities (ARIC) study and Framingham Heart Study (FHS). Clin Nutr, 2024
- Unraveling anti-atherosclerosis mechanism of anthocyanins from Xinjiang wild cherry plum (Prunus divaricata Ledeb) via network pharmacology and molecular docking. Bioresour Bioprocess, 2025